The Clinical Trials Research Office (CTRO) provides the infrastructure and facilitates the coordination necessary to support high quality clinical research in a matrix style cancer center. The science supported by the CTRO encompasses all levels and types of clinical trials, from pilot studies and phase I protocols through phase II and III protocols. These protocols may be UWCCC investigator-initiated institutional or industry sponsored clinical trials, or they may be NCI-sponsored clinical trials funded through the cooperative group, phase I, or research grant mechanisms. The CTRO infrastructure for clinical research supported by the CCSG grant is designed to facilitate and promote clinical research by providing effective mechanisms for quality control and efficiency. The UWCCC core component of the CTRO provides a basic level of protocol- specific support for all UWCCC clinical trials. This includes process coordination; protocol activation and closure; tracking by the UWCCC data base; regulatory review and compliance; patient registration and randomization; and quality assurance. The CTRO supports the Protocol Review and Monitoring System, providing checkpoints for quality control and for enforcement of the institutional authority to open and close protocols. It ensures complete reports on protocol activity and meaningful cancer center supervision of the cancer clinical research in the institution.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA014520-26
Application #
6268760
Study Section
Project Start
1998-06-24
Project End
1999-03-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
26
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Wisconsin Madison
Department
Type
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Liu, Bai; Jones, Monica; Kong, Lin et al. (2018) Evaluation of the biological activities of the IL-15 superagonist complex, ALT-803, following intravenous versus subcutaneous administration in murine models. Cytokine 107:105-112
Yu, Deyang; Yang, Shany E; Miller, Blake R et al. (2018) Short-term methionine deprivation improves metabolic health via sexually dimorphic, mTORC1-independent mechanisms. FASEB J 32:3471-3482
Carroll, Molly J; Fogg, Kaitlin C; Patel, Harin A et al. (2018) Alternatively-Activated Macrophages Upregulate Mesothelial Expression of P-Selectin to Enhance Adhesion of Ovarian Cancer Cells. Cancer Res 78:3560-3573
Ehlerding, Emily B; Grodzinski, Piotr; Cai, Weibo et al. (2018) Big Potential from Small Agents: Nanoparticles for Imaging-Based Companion Diagnostics. ACS Nano 12:2106-2121
Park, Linda; Schwei, R J; Xiong, P et al. (2018) Addressing Cultural Determinants of Health for Latino and Hmong Patients with Limited English Proficiency: Practical Strategies to Reduce Health Disparities. J Racial Ethn Health Disparities 5:536-544
Ehlerding, Emily B; Lan, Xiaoli; Cai, Weibo (2018) ""Albumin Hitchhiking"" with an Evans Blue Analog for Cancer Theranostics. Theranostics 8:812-814
Morris, Zachary S; Guy, Emily I; Werner, Lauryn R et al. (2018) Tumor-Specific Inhibition of In Situ Vaccination by Distant Untreated Tumor Sites. Cancer Immunol Res 6:825-834
Yu, Bo; Goel, Shreya; Ni, Dalong et al. (2018) Reassembly of 89 Zr-Labeled Cancer Cell Membranes into Multicompartment Membrane-Derived Liposomes for PET-Trackable Tumor-Targeted Theranostics. Adv Mater 30:e1704934
England, Christopher G; Jiang, Dawei; Ehlerding, Emily B et al. (2018) 89Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer. Eur J Nucl Med Mol Imaging 45:110-120
Rutter, Carolyn M; Kim, Jane J; Meester, Reinier G S et al. (2018) Effect of Time to Diagnostic Testing for Breast, Cervical, and Colorectal Cancer Screening Abnormalities on Screening Efficacy: A Modeling Study. Cancer Epidemiol Biomarkers Prev 27:158-164

Showing the most recent 10 out of 1528 publications